A randomized, placebo-controlled trial demonstrates the efficacy of droxidopa for the treatment of neurogenic orthostatic hypotension, but the trial's enrichment design leaves open the important question of which patients stand to benefit.
Neurogenic orthostatic hypotension is a clinical syndrome characterized by a sustained drop in blood pressure upon becoming upright that leads to symptoms of brain hypoperfusion (e.g., lightheadedness, intolerance of the upright position, generalized weakness, and visual disturbances). It results from impaired compensatory autonomic reflexes due to either loss of central pathways that regulate sympathetic drive or degeneration of postganglionic sympathetic neurons. Investigators have now evaluated droxidopa, an orally administered artificial amino acid that is converted into norepinephrine, as treatment for neurogenic orthostatic hypotension, an indication for which the drug recently received FDA approval (NEJM JW Neurol Mar 18 2014). In th…
Reviewing Author
DisclosuresGrant / Research supportNIH NeuroBioBank; ALS Association; NIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences; FDA; Department of Defense
Editorial boardsCochrane Collaboration
Leadership positions in professional societiesMuscle Study Group Executive Committee
DisclosuresGrant / Research supportNIH NeuroBioBank; ALS Association; NIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences; FDA; Department of Defense
Editorial boardsCochrane Collaboration
Leadership positions in professional societiesMuscle Study Group Executive Committee